Przejdź do treści
W Polsce: Wkrótce rekrutacjaNa świecie: Rekrutacja wkrótcePolska

Guzy lite: badanie kliniczne

Tytuł w rejestrze: Comparing Radiotherapy Dose Strategies for Symptom Relief in Large Solid Tumors

Najważniejsze informacje

Choroba
Guzy lite, Nowotwór (Solid Tumor)
Status w Polsce
Wkrótce rekrutacjarejestr nie podaje osobnego stanu dla Polski, pokazujemy stan całego badania
Status na świecie
Rekrutacja wkrótcestan całego badania w rejestrze
Wiek uczestników
od 18 lat
Płeć
kobiety i mężczyźni
Planowana liczba uczestników
łącznie 426
Terminy (planowane)
grudzień 2026 - grudzień 2031
Kraje
Polska 1: Polska
Numer w rejestrze
NCT07908914 (ClinicalTrials.gov)

Gdzie prowadzone jest badanie

Ośrodki prowadzące badanie w Polsce (1), alfabetycznie według miejscowości:

Zapytaj o udział w badaniu

Najszybciej: porozmawiaj z naszym doradcą ds. badań.

Zadzwoń do naszego specjalisty+48 664 930 800pon-pt: 9:00 - 18:00

albo zostaw numer, oddzwonimy:

O Twoim zdrowiu porozmawiamy dopiero przez telefon, po Twojej zgodzie. W formularzu nie podajesz takich informacji.

rekrutuje wkrótce nie rekrutuje lub brak danych

Kliknij kropkę, żeby zobaczyć ośrodki w mieście.

Więcej badań w tych miastach:

Stan rekrutacji pochodzi z rejestrów badań i może się zmienić szybciej, niż zaktualizuje go sponsor. Nasz doradca sprawdzi aktualny stan w wybranym ośrodku. Nie publikujemy nazwisk lekarzy ani ich danych kontaktowych.

Cel badania

Opis z rejestru (w języku angielskim):

This study will compare three ways of giving radiotherapy to relieve symptoms caused by a large solid tumor. Radiotherapy uses radiation to treat cancer. Researchers want to find out whether LATTICE radiotherapy, which gives a higher dose to small areas inside a tumor while treating the rest with a lower dose, improves symptom relief compared with two treatments that give a more even dose.

The study plans to enroll 426 adults. One tumor must be at least 7 centimeters across and have a volume of at least 100 cubic centimeters. It must cause a symptom rated at least 4 on a 0-to-10 severity scale. The symptom may be pain, pressure or fullness, difficulty breathing or swallowing, bleeding, or difficulty with an activity because of the tumor. All three study treatments must be technically suitable for the person.

Participants will be assigned by chance, with an equal chance of receiving one of three treatments:

* A total dose of 20 gray over five treatment sessions, given evenly to the treatment area. * A total dose of 25 gray over five sessions, given evenly to the treatment area. * LATTICE radiotherapy: 20 gray over five sessions to the treatment area, with selected small regions inside the tumor receiving a total dose of 66.7 gray during those same sessions.

Gray is a unit of radiation dose. The 66.7-gray dose is the total dose to the selected regions, not an additional 66.7 gray on top of 20 gray. Each treatment is given once a day on five consecutive working days. Participants and their treatment teams will know which treatment has been assigned.

Before assignment, each participant will choose the single tumor-related symptom they most want treatment to improve. The main assessment is about eight weeks after treatment. A response requires a decrease of at least 2 points in this symptom score, while the participant remains alive and has not needed unplanned local treatment of the study tumor through day 63 after the final session. Death or this additional local treatment counts as nonresponse, even if symptoms improved earlier. A missing symptom score in a participant who is alive and has not needed this treatment is handled separately in the analysis.

Researchers will also assess how quickly symptom relief starts, how long it lasts, quality of life, side effects, tumor changes on scans, further treatment, hospital use and survival. Medical care needed for comfort or safety will not be withheld. Some questionnaires can be completed by telephone if a participant cannot or does not wish to attend; telephone calls do not replace required examinations, blood tests or scans.

Hospital stays and days alive outside hospital are assessed during the first 90 days after assignment, including people who do not start or finish radiotherapy. Side effects are recorded before treatment and during follow-up; the acute treatment-related assessment extends to 90 days after the last radiotherapy session actually received. The first 15 participants assigned to LATTICE will receive additional treatment-plan and safety review within the randomized study. Participants will be followed for at least 12 months, where survival permits, with record-based or direct follow-up extending to 24 months when possible. A planned review of missing outcome information, without examining treatment effects, may increase enrollment to a maximum of 480 participants.

Leczenie w badaniu

Lek / interwencjaRolaPostać, podanie
Homogeneous External-Beam Radiotherapy, 20 Gy in Five FractionsRadioterapia
Homogeneous External-Beam Radiotherapy, 25 Gy in Five FractionsRadioterapia
LATTICE Radiotherapy, 20 Gy With a Simultaneous Integrated Boost to 66.7 Gy in Five FractionsRadioterapia

Kryteria udziału

Kryteria w języku angielskim, tak jak w rejestrze.

Kryteria włączenia kto może wziąć udział (13)

  1. Age at least 18 years at consent.
  2. Histologically or cytologically confirmed solid malignancy. A repeat biopsy of a radiographically typical metastasis is not required in a participant with an established cancer diagnosis when the multidisciplinary team documents that biopsy would not change care.
  3. One index lesion with a maximum three-dimensional diameter of at least 7.0 centimeters on baseline planning computed tomography or co-registered diagnostic imaging, measured in any orthogonal plane.
  4. Planning gross tumor volume of the index lesion at least 100 cubic centimeters, documented before randomization.
  5. A target symptom clinically attributable to the index lesion and rated at least 4 on a 0-to-10 numeric rating scale at baseline. Allowed categories are pain, pressure/fullness, dyspnea, dysphagia, bleeding burden or lesion-related functional limitation. Another symptom requires documented confirmation by the Principal Investigator or a qualified delegated physician that attribution is reliable; exact wording is fixed before randomization.
  6. The treating radiation oncologist judges that local radiotherapy is appropriate and its expected benefit is not outweighed by its burden.
  7. Eastern Cooperative Oncology Group performance status 0-3.
  8. Investigator-estimated life expectancy at least 12 weeks, supported by a locally accepted prognostic tool where available.
  9. Planning computed tomography and technical review confirm that all three randomized regimens could meet every hard organ-at-risk constraint and every mandatory target-coverage minimum, and the lesion can accommodate at least three complete protocol-conforming LATTICE high-dose regions.
  10. Ability to undergo simulation, immobilization and image guidance, and receive one fraction daily on five consecutive working days, with planned completion within seven calendar days of the first fraction and a protocol-permitted maximum of ten calendar days after a documented interruption.
  11. Adequate clinical stability and laboratory status for treatment, including the protocol tumor lysis syndrome risk assessment and laboratory panel.
  12. For participants of childbearing potential, a negative pregnancy test according to institutional policy and agreement to avoid pregnancy during the protocol-defined radiation-risk period.
  13. Ability to understand study procedures and provide written informed consent. Reading or electronic-completion assistance is allowed if responses remain the participant's own.

Kryteria wyłączenia kto nie może wziąć udziału (13)

  1. A primary central nervous system tumor, brain metastasis or spinal-canal/intramedullary target requiring a central nervous system-specific stereotactic protocol.
  2. Hematologic malignancy, including lymphoma, leukemia or myeloma, as the index lesion.
  3. An oncologic emergency in which randomization could delay required decompression, stabilization, surgery, embolization, hemostatic intervention or immediate conventional radiotherapy. Examples include unstable spinal cord or cauda equina compression, impending airway loss, uncontrolled life-threatening bleeding, bowel perforation or an unstable pathological fracture.
  4. Previous radiotherapy to the index lesion with clinically relevant overlap. Overlapping reirradiation is excluded in the current protocol; a future separately approved amendment would be required to permit it.
  5. Inability to meet a hard organ-at-risk constraint or a mandatory target-coverage minimum in any arm, place the required number of compliant high-dose regions, or adequately visualize or manage target motion.
  6. An arrangement in which a critical serial organ or hollow-viscus organ would enter a high-dose region and safe deletion of that region or translation of the locked grid would leave fewer than three valid regions.
  7. Eastern Cooperative Oncology Group performance status 4 or estimated life expectancy less than 12 weeks.
  8. Pregnancy or breastfeeding when treatment poses clinically relevant fetal or infant risk.
  9. A genetic or connective-tissue condition associated with unacceptable radiosensitivity when the investigator considers hypofractionation unsafe.
  10. Uncontrolled infection, bleeding disorder, metabolic abnormality, organ failure or another illness that makes protocol radiotherapy unsafe.
  11. Clinical or laboratory tumor lysis syndrome at baseline.
  12. Concurrent investigational radiosensitizer or systemic treatment whose timing cannot meet protocol washout or hold requirements, unless prospectively approved by the Principal Investigator before randomization.
  13. Another condition that, in the investigator's documented judgment, prevents reliable consent, protocol treatment or primary-outcome collection and cannot be addressed by reasonable support or the telephone contingency.

To główne kryteria z rejestru. Pełną listę i ostateczną decyzję o udziale ustala lekarz prowadzący badanie.

Zapytaj o udział w tym badaniu

Zadzwoń, a nasz doradca ds. badań sprawdzi z Tobą wstępnie kryteria i pomoże skontaktować się z ośrodkiem. Kwalifikację zawsze przeprowadza lekarz w ośrodku. Udział w badaniu jest bezpłatny i dobrowolny.

Wolisz, żebyśmy oddzwonili? Zostaw numer

O Twoim zdrowiu porozmawiamy dopiero przez telefon, po Twojej zgodzie. W formularzu nie podajesz takich informacji.

Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.

Inne badania: guzy lite

RekrutujeFaza II/III

Rak prostaty: badanie kliniczne fazy II/III

PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer

Polska

Miasta: ZamośćWiek: od 18 latSponsor: Affidea Nu-med Center of Oncological DIagnostics and Therapy

W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza II

Badanie fazy II leku pemetrexed i dexamethasone

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Badane leki: pemetrexeddexamethasonepembrolizumabadagrasibPolskaAustraliaBelgiaBrazyliaChinyFrancjaGrecjaHiszpania+15

Miasta: Gdańsk, LublinWiek: od 18 latSponsor: Bristol-Myers Squibb Services Unlimited Company

W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III

Zakrzepica żył głębokich: badanie fazy III leku REGN7508

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

Badane leki: REGN7508PolskaAustraliaBelgiaBrazyliaBułgariaCzechyFrancjaGruzja+10

Miasta: Gdańsk, Koszalin, Kraków, Olsztyn i 4 inne miastaWiek: od 18 latSponsor: Regeneron Pharmaceuticals Inc.

Wszystkie badania: guzy lite

Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 11 listopada 2026.